SmartTarget device for the detection of prostate cancer
The SmartTarget technology enables image-directed tumour targeting during minimally invasive biopsy procedures for prostate cancer patients.
6 December 2019
The CE certified SmartTarget system is an image fusion device for guiding targeted, transperineal prostate biopsy. Designed and developed by biomedical engineers at 911±¬ÁÏÍø and urologists at NHS Trust hospital University College London Hospital (UCLH), the technology enables image-directed tumour targeting during minimally invasive biopsy procedures for prostate cancer patients and has undergone extensive clinical evaluation in over 200 patients at 911±¬ÁÏÍøH.
Led by Professor Mark Emberton, Dean of the UCL Faculty of Medical Sciences, and Professor Caroline Moore (UCL Division of Surgery & Interventional Science), the research demonstrated that the use of multi-parametric MRI (mpMRI) as an alternative method is much more effective and significantly cuts NHS costs.Â